Defunct Company
Total Trials
14
As Lead Sponsor
3
As Collaborator
11
Total Enrollment
3,476
NCT02491606
Evaluation of Weekly Tafenoquine
Phase: Phase 2
Role: Collaborator
Start: May 31, 1997
Completion: Sep 30, 1998
NCT00003733
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
Role: Lead Sponsor
Start: Dec 31, 1997
Completion: Not specified
NCT01559753
Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment
Phase: Phase 4
Start: Jan 31, 1998
Completion: Nov 30, 2002
NCT00005792
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase: Phase 1
Start: Jun 2, 1998
Completion: Nov 1, 2018
NCT00100477
Use of Topotecan in Patients With Refractory Acute Leukemia
Start: Aug 31, 1998
Completion: Jun 30, 2001
NCT02488902
A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum
Completion: Mar 31, 2003
NCT00005793
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
Phase: Phase 1/2
Start: Jul 31, 1999
Completion: Nov 30, 2006
NCT02488980
An Evaluation of Weekly Tafenoquine
Start: May 31, 2000
NCT02526615
Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes
Start: Oct 31, 2000
Completion: Dec 31, 2001
NCT00032487
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Phase: Phase 3
Start: Dec 1, 2000
Completion: May 30, 2008
NCT00018759
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients
Start: Mar 31, 2001
Completion: Oct 31, 2003
NCT01039025
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
Start: Feb 18, 2002
Completion: May 19, 2006